Adherium Advances Smart Respiratory Care with AU$7.52 Million Equity Raise
Adherium Limited (ASX: ADR) is pursuing an equity raise of approximately AU$7.52 million to accelerate the commercial expansion of its digital respiratory platform and strengthen its Remote Patient Monitoring (RPM) operations. The company operates in a substantial U.S. market where nearly 40 million individuals live with chronic respiratory conditions such as asthma and COPD. Poor adherence to prescribed inhaler therapy remains a major contributor to avoidable hospitalisations, emergency visits, and escalating healthcare costs.
Adherium’s Hailie Smartinhaler platform combines connected inhaler devices, behavioural prompts, real-time usage tracking, and clinical data analytics to improve medication compliance and patient outcomes. Interim results from the iCARE study demonstrated a 235% improvement in adherence compared with conventional benchmarks. With more than 2,100 active RPM patients and strategic partnerships that provide access to over one million potential respiratory patients, the company aims to exceed 10,000 RPM patients by the end of 2026. Funds raised will support working capital, RPM scale-up, and expansion into higher-margin value-based care contracts with U.S. payers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Adherium Advances Smart Respiratory Care with AU$7.52 Million Equity Raise
Adherium Limited (ASX: ADR) is pursuing an equity raise of approximately AU$7.52 million to accelerate the commercial expansion of its digital respiratory platform and strengthen its Remote Patient Monitoring (RPM) operations. The company operates in a substantial U.S. market where nearly 40 million individuals live with chronic respiratory conditions such as asthma and COPD. Poor adherence to prescribed inhaler therapy remains a major contributor to avoidable hospitalisations, emergency visits, and escalating healthcare costs.
Adherium’s Hailie Smartinhaler platform combines connected inhaler devices, behavioural prompts, real-time usage tracking, and clinical data analytics to improve medication compliance and patient outcomes. Interim results from the iCARE study demonstrated a 235% improvement in adherence compared with conventional benchmarks. With more than 2,100 active RPM patients and strategic partnerships that provide access to over one million potential respiratory patients, the company aims to exceed 10,000 RPM patients by the end of 2026. Funds raised will support working capital, RPM scale-up, and expansion into higher-margin value-based care contracts with U.S. payers.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au